187 related articles for article (PubMed ID: 35747941)
41. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
Martin G
Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
[TBL] [Abstract][Full Text] [Related]
42. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
43. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
44. Deucravacitinib: First Approval.
Hoy SM
Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
[TBL] [Abstract][Full Text] [Related]
45. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.
Diogo D; Bastarache L; Liao KP; Graham RR; Fulton RS; Greenberg JD; Eyre S; Bowes J; Cui J; Lee A; Pappas DA; Kremer JM; Barton A; Coenen MJ; Franke B; Kiemeney LA; Mariette X; Richard-Miceli C; Canhão H; Fonseca JE; de Vries N; Tak PP; Crusius JB; Nurmohamed MT; Kurreeman F; Mikuls TR; Okada Y; Stahl EA; Larson DE; Deluca TL; O'Laughlin M; Fronick CC; Fulton LL; Kosoy R; Ransom M; Bhangale TR; Ortmann W; Cagan A; Gainer V; Karlson EW; Kohane I; Murphy SN; Martin J; Zhernakova A; Klareskog L; Padyukov L; Worthington J; Mardis ER; Seldin MF; Gregersen PK; Behrens T; Raychaudhuri S; Denny JC; Plenge RM
PLoS One; 2015; 10(4):e0122271. PubMed ID: 25849893
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis.
Yin Q; Wu LC; Zheng L; Han MY; Hu LY; Zhao PP; Bai WY; Zhu XW; Xia JW; Wang XB; Zhang XW; Zheng HF
Arch Dermatol Res; 2018 Nov; 310(9):711-728. PubMed ID: 30171347
[TBL] [Abstract][Full Text] [Related]
47. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
48. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
50. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Papp K; Gordon K; Thaçi D; Morita A; Gooderham M; Foley P; Girgis IG; Kundu S; Banerjee S
N Engl J Med; 2018 Oct; 379(14):1313-1321. PubMed ID: 30205746
[TBL] [Abstract][Full Text] [Related]
51. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
52. Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases.
Tao JH; Zou YF; Feng XL; Li J; Wang F; Pan FM; Ye DQ
Mol Biol Rep; 2011 Oct; 38(7):4663-72. PubMed ID: 21140222
[TBL] [Abstract][Full Text] [Related]
53. Identification of rare coding variants in
Motegi T; Kochi Y; Matsuda K; Kubo M; Yamamoto K; Momozawa Y
Ann Rheum Dis; 2019 Aug; 78(8):1062-1069. PubMed ID: 31118190
[TBL] [Abstract][Full Text] [Related]
54. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
55. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Chang Y; Xu S; Ding K
J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
[TBL] [Abstract][Full Text] [Related]
56. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
Wang J; Batista VS; Bunick CG
bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
[TBL] [Abstract][Full Text] [Related]
57. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
[TBL] [Abstract][Full Text] [Related]
58. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.
Rothman N; Skibola CF; Wang SS; Morgan G; Lan Q; Smith MT; Spinelli JJ; Willett E; De Sanjose S; Cocco P; Berndt SI; Brennan P; Brooks-Wilson A; Wacholder S; Becker N; Hartge P; Zheng T; Roman E; Holly EA; Boffetta P; Armstrong B; Cozen W; Linet M; Bosch FX; Ennas MG; Holford TR; Gallagher RP; Rollinson S; Bracci PM; Cerhan JR; Whitby D; Moore PS; Leaderer B; Lai A; Spink C; Davis S; Bosch R; Scarpa A; Zhang Y; Severson RK; Yeager M; Chanock S; Nieters A
Lancet Oncol; 2006 Jan; 7(1):27-38. PubMed ID: 16389181
[TBL] [Abstract][Full Text] [Related]
59. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
60. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
